Evaluating Modes of Influenza Transmission 2b Baseline SAR
NCT07342556 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80
Last updated 2026-01-15
Summary
This is a research study to investigate how influenza transmits from person-to-person. Participation as a healthy "Recipient" in this study involves:
* Home semi-quarantine lasting about 14 days during which the participants must wear an N95 in class and take other precautions
* Daily assessments and clinic visits for 14 days
* Spending every weekday evening for about 14 days from around 6 - 10 pm, including a provided dinner, in a controlled environment. There may be additional sessions and different required participation times on weekends
* Exposure to people infected with influenza in the controlled environment
* Three blood draws, at the start, at the end of 14 days, and about a month after the end.
* A follow-up clinic visits one month after the end of home semi-quarantine
* A two-month follow-up phone call. This study may increase the participant's risk of catching influenza.
If the participants get infected during the study, the investigators may:
* Provide the participants with a prescription for antiviral medication or
* Refer the participants for medical care
* Ask the participants to become a Donor and expose other Recipients.
The participants will be compensated for their time and active participation in the study; however, they may not personally benefit from the study. While the participants may receive supportive care for an infection resulting from the study, this is not meant to replace their regular medical care. If the participants become very ill and need referral for medical care, they or their medical insurance will be billed.
If the participants are someone who recently became infected with influenza either through their daily activities or by participating in this study as a Recipient, they are invited to participate in this research study as a Donor and interact with a group of health participants in a controlled environment. Participation in this study as a Donor involves exposing Recipients for at least one and up to five days including:
* Attend exposure events in a controlled environment
* Weekday evenings from around 6-10 pm
* Additional day and evening events on weekends
* Events include a provided dinner
* Daily assessments and clinic visits for 1 to 5 days
* Provide exhaled breath samples for 30 to 60 minutes
* Three blood draws, at the start and end of exposure events, and about a month after the end
* A follow-up clinic visit one month after their last exposure event
* A two-month follow-up phone call
If the participants experience severe symptoms related to their influenza infection, we may:
* Provide the participants with a prescription for antiviral medication or
* Refer the participants for medical care
The participants will be compensated for their time and active participation in the study; however, they may not personally benefit from the study. While the participants may receive supportive care for their influenza infection, this is not meant to replace their regular medical care. If the participants become very ill and need referral for medical care, they or their medical insurance will be billed.
Conditions
- Influenza (Healthy Volunteers)
Interventions
- OTHER
-
Exposure to Donors with naturally acquired influenza virus infection
Recipients are exposed to Donors in a controlled environment while performing prescribed activities, including playing cards and other games, and periodically shaking hands with Donors and rubbing their own nose and eyes.
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
collaborator NIH -
University of Maryland, College Park
lead OTHER
Principal Investigators
-
Donald K Milton, MD, DrPH · University of Maryland School of Public Health
Study Design
- Allocation
- NA
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 49 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-01-31
- Primary Completion
- 2026-03-31
- Completion
- 2026-05-31
Countries
- United States
Study Locations
More Related Trials
-
Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers
NCT02594189 ·Status: COMPLETED ·Phase: PHASE1
-
Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain
NCT06613737 ·Status: COMPLETED ·Phase: NA
-
Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model
NCT02525055 ·Status: COMPLETED ·Phase: NA
-
Dose, Safety, and Pathogenicity of a New Influenza B Strain
NCT06254820 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7
NCT00922259 ·Status: COMPLETED ·Phase: PHASE1
-
Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
NCT02572817 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Exclusion Criteria in a University Population
NCT01472536 ·Status: COMPLETED ·Phase: NA
-
Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age
NCT00192140 ·Status: COMPLETED ·Phase: PHASE4
-
Influenza Immunity in Children
NCT02559505 ·Status: COMPLETED ·Phase: NA
-
A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults
NCT02623322 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine
NCT00722774 ·Status: COMPLETED ·Phase: PHASE1
-
Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain
NCT05572450 ·Status: COMPLETED ·Phase: NA
-
Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza?
NCT01001325 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
NCT01052480 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects
NCT00845429 ·Status: COMPLETED ·Phase: PHASE2
-
Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain
NCT04978454 ·Status: COMPLETED ·Phase: PHASE1
-
Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting
NCT02478905 ·Status: COMPLETED
-
Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.
NCT01262079 ·Status: COMPLETED
-
B-cell Immunity to Influenza (SLVP017)- Year 1, 2009
NCT02133781 ·Status: COMPLETED ·Phase: PHASE4
-
Establishing a Controlled Human Infection Model for Influenza H3N2 as a Foundation for Pandemic Preparedness
NCT07305207 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant
NCT02957656 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.
NCT00192309 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults
NCT00125944 ·Status: COMPLETED ·Phase: PHASE3
-
H7N9 Boost in Healthy Adults
NCT02586792 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
NCT00545532 ·Status: COMPLETED ·Phase: PHASE3